Summary
It is now generally accepted by neurologists that most transient ischaemic attacks, particularly in the carotid artery territory, have a thromboembolic basis. These emboli are, for the most part, fibrin-platelet aggregates. Others which contain atheromatous debris are more likely to produce longer lasting neurological deficits. If one assumes this hypothesis then it is reasonable to employ drugs which interfere with platelet aggregation in order to prevent cerebrovascular symptoms and signs. Acetylsalicylic acid (aspirin) prevents aggregation by inhibiting the ‘release reaction’ initiated by thromboxane A2. This inhibition lasts for the life of the affected platelets. Recent trials in the United States and Canada have demonstrated a positive clinical benefit from the employment of aspirin in patients suffering from transient cerebral ischaemic attacks and amaurosis fugax. There was a reduction or cessation of the attacks in both males and females and a 50% reduction of stroke morbidity and mortality in males.
Similar content being viewed by others
References
Fields, W.S.; Lemak, N.A.; Frankowski, R.F. and Hardy, R.J.: Controlled trial of aspirin in cerebral ischemia. Stroke 8: 301–316 (1977).
Fields, W.S.; Lemak, N.A.; Frankowski, R.F. and Hardy, R.J.: Controlled trial of aspirin in cerebral ischemia. Part II: Surgical group. Stroke 9: 309–319 (1978).
Fisher, C.M.: Observations of the fundus oculi in transient monocular blindness. Neurology 9: 333 (1959).
Genton, E.; Barnett, H.J.M.; Fields, W.S.; Gent, M. and Hoak, J.C.: XIV. Cerebral ischemia: The role of thrombosis and of antithrombotic therapy. Stroke 9: 147–175 (1977).
Hass, W.K.: Occlusive cerebrovascular disease. Medical Clinics of North America 56: 1281 (1972).
Hass, W.K.; Fields, W.S.; North, R.R.; Kricheff, I.I.; Chase, N.E. and Bauer, R.B.: Joint study of extracranial arterial occlusion. II. Arteriography, techniques, sites, and complications. Journal of the American Medical Association 203: 159 (1968).
Moncada, S. and Korbut, R.: Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1: 1286–1288 (1978).
Rasmussen, H. and Goodman, D.B.P.: Relationships between calcium and cyclic nucleotides in cell activation. Physiological Reviews 57: 422–509 (1977).
Ross, R. and Glomset, J.A.: Pathogenesis of atherosclerosis. New England Journal of Medicine 295: 369–377 and 420–425 (1976).
The Canadian Cooperative Study Group: A randomized trial of aspirin and sulfinpyrazone in threatened stroke. New England Journal of Medicine 299: 53–59 (1978).
Toole, J.F.; Janeway, R.; Choi, K.; Cordell, R.; Davis, D.; Johnston, F. and Miller, H.S.: Transient ischemic attacks due to atherosclerosis, a prospective study of 160 patients. Archives of Neurology 32: 5–12 (1975).
Verstraete, M.: Are agents affecting platelet functions clinically useful? American Journal of Medicine 61: 897–914 (1976).
Weibel, J. and Fields, W.S.: Atlas of arteriography in occlusive cerebrovascular disease (Georg Thieme Verlag, Stuttgart 1969).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fields, W.S. Role of Antiplatelet Agents in Cerebrovascular Disease. Drugs 18, 150–155 (1979). https://doi.org/10.2165/00003495-197918020-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-197918020-00007